The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 6 of the 25 sources its claims cite were checked for support.
Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans
Abstract
The sterol pathway in Candida albicans is the target for several classes of antifungal drugs. Intermediates in the sterol pathway are involved in ergosterol synthesis, prenylation and dolichol synthesis. This study examines gene expression of the sterol pathway in response to lovastatin, an inhibitor of HMG-CoA reductase (Hmg1p), and fluconazole, an inhibitor of 14 alpha-lanosterol demethylase (Erg11p). Minimum inhibitory concentration (MIC) studies indicated that lovastatin acts synergistically with fluconazole in vitro. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) results indicated that genes in the early part of the sterol pathway, such as HMG1 and ERG20, did not alter expression in the presence of both lovastatin and fluconazole, whereas genes in the later part of the sterol pathway, such as ERG9 and ERG11, had increased expression in response to these drugs in mid-logarithmic growth. Genes involved in prenylation, such as RAM1 and RAM2, also respond to these drugs in mid-logarithmic growth, although another prenylation gene, CDC43, was not affected. After 24 h of growth, the relative expression of ERG20, ERG9, and ERG11 remained unchanged or increased in the presence of both drugs, while all other genes decreased in expression under all drug treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 17 Not checked · 77 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“a finding that is consistent with the findings of previous work with itraconazole [21].”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Effect o f fluconazole and lovastatin on R NA levels for genes in the ergosterol and prenylation pathways
What the sources say
- Supportedcites [21] DeBacker MD., 2001, Antimicrob Agent Chemother source
The Results and Discussion report that itraconazole treatment increased expression of both ERG9 and ERG11 in Candida albicans. This supports the cited comparison with the fluconazole finding; it does not attribute the fluconazole study’s threefold magnitude to the itraconazole study. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The combined use of lovastatin and itraconazole may lead to 1-habdomyolysis as described in a previous clinical report [25].”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Discussion
What the sources say
- Supportedcites [25] source
The clinical report describes severe rhabdomyolysis after itraconazole was added to a stable regimen containing lovastatin and niacin. The authors say the cause of the reaction is unclear, which is consistent with the citing sentence’s cautious “may lead to” wording. (LLM, conf=0.92)
hedgedstates a possible causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In trials in which different parts of the sterol pathway were perturbed, semi-quantitative RT-PCR indicated that the relative expression of ERG9 and ERGll was increased in the presence of fluconazole in midlogarithmic growth, consistent with the results of a previous study [20,21].”
- Also stated in: § Discussion · plain
“Consistent with previous studies [20,21], the present study showed that expression of CaERG9 and CaERGll increased with fluconazole treatment of the cells.”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Discussion
What the sources say
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The Results section reports that fluconazole increased expression of both ERG9 and ERG11 in C. albicans. The Methods say treatment began with logarithmic-phase cultures, but the paper does not establish the increase specifically during mid-logarithmic growth; the Discussion says it was most readily observed in late-logarithmic-phase cultures. Page numbers were not available in our copy. (LLM, conf=0.83)
- Partly supportedcites [21] DeBacker MD., 2001, Antimicrob Agent Chemother sourceExperimental — accuracy not yet measured
The Results and Discussion report increased ERG9 and ERG11 expression in Candida albicans after itraconazole treatment, supporting the direction of the expression change. They do not establish that fluconazole caused that change during mid-logarithmic growth; the paper also notes that different azoles can have different effects on gene expression. Page numbers were not available in our copy's passages. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“With S. cereuisiae, 10 pglml of lovastatin lowered the MIC of ketoconazole, clotrimazole and miconazole sixto 32-fold [13].”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Discussion
What the sources say
- Supportedcites [13] Lorenz RT, 1990, Antimicrob Agent Chemother source
The Results and Discussion passage reports that, in S. cerevisiae strain 2180-1A, 10 μg/ml lovastatin reduced the MICs of clotrimazole, ketoconazole, and miconazole by 6-, 10-, and 32-fold, respectively. This matches the cited 6- to 32-fold range. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fluconazole MIC in the presence of 5 pgl ml of lovastatin decreased two-and fourfold in RPMI and 16-fold in YEPD at 24 and 48 h, respectively (Table 2).”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Lovastatin and fluconazole MIC
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
64 more claims
Create a free account to see all 99 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 16
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this context, studies on the interaction between azoles and statins have gained renewed attention.10,11,27,32,37”
From Synergistic antifungal activity of statin–azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification (2013) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pitavastatin’s fluconazole chemosensitizing activity was even more superior than the other pharmacologically-related statin drugs, which were reported to have fluconazole-chemosensitizing activities26,27.”
From Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species (2020) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, synergy between simvastatin and azoles has been described for planktonically growing yeast cultures46 as is the case for other statin-azole combinations47.”
From Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms (2016) · cites this paper as [47]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies suggested that lovastatin and pravastatin disrupted mitochondrial function due to media with glucose as a carbon source, which exhibited minor growth inhibition. The inhibition is significantly enhanced in media with ethanol as the carbon source [78,79].”
From Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species (2024) · cites this paper as [78]
Experimental — accuracy not yet measuredIn the citing paper
“Notably, the azole chemosensitizing activity of statins has been attributed to their ability to interfere with the fungal ergosterol biosynthesis26,47.”
From Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species (2020) · cites this paper as [26]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > In vitro susceptibility testing
“MIC were defined as an 80% reduction in optical density compared with the growth control at 24 and 48 h.”
§ Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans > Discussion
“"Minimal inhibitory concentration of a drug that reduces growth to 80% compared to the control.”
Citations
Cites
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Molecular Cloning. A Laboratory Manual
Wood, E. (1983) · Biochemical Education · doi:10.1016/0307-4412(83)90068-7 · Cited by 29,533
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035
Antibiotics in laboratory medicine
Hausler, W. J. (1997) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00063-1 · Cited by 1,029
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
PROTEIN PRENYLATION: GENES, ENZYMES, TARGETS, AND FUNCTIONS
Schafer, W. R., & Rine, J. (1992) · Annual Review of Genetics · doi:10.1146/annurev.ge.26.120192.001233 · Cited by 377
PHYSIOLOGICAL IMPLICATIONS OF STEROL BIOSYNTHESIS IN YEAST
Parks, L. W., & Casey, W. M. (1995) · Annual Review of Microbiology · doi:10.1146/annurev.mi.49.100195.000523 · Cited by 336
Research works printed but not linked: 2
- Odds FC., 1988, Candida and Candidosis: A Review and Bibliography
- Ishii N, 1996, GenBank
Cited by
Systematic exploration of essential yeast gene function with temperature-sensitive mutants
Li, Z., Vizeacoumar, F. J., Bahr, S., Li, J., Warringer, J., Vizeacoumar, F. S., Min, R., VanderSluis, B., Bellay, J., DeVit, M., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1832 · Cited by 413
Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis
Hackam, D. G., Mamdani, M., Li, P., & Redelmeier, D. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68041-0 · Cited by 321
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291
Statins: a viable candidate for host-directed therapy against infectious diseases
Parihar, S. P., Guler, R., & Brombacher, F. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0094-3 · Cited by 161
An overview of the bioactivity of monacolin K / lovastatin
Xiong, Z., Cao, X., Wen, Q., Chen, Z., Cheng, Z., Huang, X., Zhang, Y., Long, C., Zhang, Y., & Huang, Z. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110585 · Cited by 131
Metadata
- Authors
- Song, J. L., Lyons, C. N., Holleman, S., Oliver, B. G., & White, T. C.
- Affiliations
- University of Washington (US)
- Center for Infectious Disease Research (US)
- Corresponding author
- Song, Jia L.
- Venue
- Medical Mycology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01
- Volume
- 41
- Issue
- 5
- Pages
- 417-425
- ISSN
- 0268-1218 (ISSN-L)
- 1369-3786
- 1460-2709
- OpenAlex
- W2016567739
- Semantic Scholar
- b0cad2a295a5385a78cb3c6a388274a69c4f4a4c
- Cited by
- 62
- References
- 30
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medical Mycology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (T32AI007509)
- National Institute of Dental and Craniofacial Research (R01DE011367, R01DE014161)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fluconazole, lovastatin, Candida albicans, antifungal synergy, ergosterol biosynthesis, prenylation, HMG-CoA reductase inhibition, ERG11, HMG1, gene expression, minimum inhibitory concentration
- MeSH terms
- Base Sequence, Candida albicans, Drug Synergism, Ergosterol, Lovastatin, Microbial Sensitivity Tests, Fluconazole, Gene Expression Regulation, Fungal, Protein Prenylation, DNA Primers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-03, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-03 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. https://app.cochat.ai/papers/10.1080/1369378031000137233
- The paper
- Song, J. L., Lyons, C. N., Holleman, S., Oliver, B. G., & White, T. C. (2003). Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Medical Mycology. https://doi.org/10.1080/1369378031000137233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.